Edinburgh Napier University

  To assess the value of antenatal screening to detect neonatal alloimmune thrombocytopenia (NAIT) due to anti-HPA-1a, a prospective study was carried out to quantify the potential clinical benefits and determine whether screening would be cost-effective.
An observational prospective controlled study was carried out on 26,506 pregnant women over 2 years. HPA-1a phenotyping was performed in the first trimester and women confirmed HPA-1a-negative were tested for anti-HPA-1a during pregnancy, at delivery, and 10 to 14 days after birth. Babies of HPA-1a-negative women were tested at delivery for thrombocytopenia and examined for signs of bleeding. Economic evaluation was undertaken on the basis of the data collected during the study
Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a - ResearchGate. Available from: http://www.researchgate.net/publication/7400069_Prospective_epidemiologic_study_of_the_outcome_and_cost-effectiveness_of_antenatal_screening_to_detect_neonatal_alloimmune_thrombocytopenia_due_to_anti-HPA-1a [accessed Nov 13, 2015].